Immunocore's second PRAME cell therapy heads to a safety readout in H2 2026
IMC-P115C, a half-life-extended PRAME binder, is a dose-escalation trial testing tolerability, not efficacy, and it follows the company's more advanced PRAME asset brenetafusp.
Executive Summary
- Immunocore is heading toward data from a dose-escalation trial whose primary measures are all tolerability endpoints, so the readout will establish how the regimen is tolerated, not whether it works.
- The trial tests the company's second distinct PRAME-targeting modality, positioned behind a more advanced PRAME program already in Phase 3 testing.
- The PRAME target has several clinical-stage cell-therapy and TCR-T programs, but none is a currently active industry Phase 1 or later trial in this indication and target combination, which places this readout in a mechanistically sparse corner of an otherwise active target.
- The trial remains actively recruiting with enrollment tracking flat against its anticipated target and no protocol instability, which is the routine profile for an early-phase dose-escalation study, not a signal of concern.
The catalyst
Immunocore said in its May 6, 2026 first-quarter update that it expects to present Phase 1/2 data from the IMC-P115C trial in advanced tumors in the second half of 2026. The trial in question, NCT07156136, is a Phase 1 dose-escalation study of IMC-P115C, a half-life-extended PRAME-A02 binder, in HLA-A*02:01-positive, PRAME-positive advanced or unresectable tumors. The trial's four primary endpoints are the percentage of participants with a dose interruption, reduction, or discontinuation, the percentage with adverse events, the percentage with dose-limiting toxicities, and the percentage with serious adverse events. Efficacy measures including objective response, duration of response, and progression-free survival are listed as secondary endpoints. Immunocore+1Immunocore reports first quarter financial results and provides a business updateMay 6, 2026Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial status
The trial has been recruiting since November 7, 2024, across sites in Spain, Australia, France, and Italy, and carries an anticipated enrollment of 140 patients. Its primary completion date is registered as September 30, 2027, more than a year after the stated H2-2026 data window, consistent with an early readout being drawn from an interim slice of the dose-escalation cohort rather than the full enrolled population. Enrollment has held flat at its anticipated 140-patient target with no growth or contraction recorded, and the protocol has logged no eligibility, endpoint, or completion-date amendments since the study was first posted in September 2025, a stable profile typical for a trial still in dose escalation. NCT07156136Study of IMC-P115C in Advanced PRAME-Positive CancersNCT07156136
Portfolio context
IMC-P115C is Immunocore's second PRAME-targeting clinical asset. The company's lead PRAME program, brenetafusp (IMC-F106C), is already in a Phase 3 trial (PRISM-MEL-301, NCT06112314) comparing it against nivolumab regimens in untreated advanced melanoma, with a separate Phase 1/2 -tumor readout for brenetafusp also flagged for the second half of 2026 in the same Immunocore disclosure. IMC-P115C uses a distinct modality, a half-life-extended PRAME binder rather than the bispecific format behind brenetafusp, positioning this readout as a test of whether the PRAME target supports more than one drug format in the same company's pipeline. ImmunocoreImmunocore reports first quarter financial results and provides a business updateMay 6, 2026
Competitive frame
PRAME has drawn a range of modalities in clinical testing, including TCR-T cell therapies from TScan Therapeutics and Medigene, a non-CAR cell therapy from Immatics (IMA203), and cancer vaccines from GlaxoSmithKline, but no other industry trial currently combines the PRAME target with this trial's advanced--tumor, HLA-A*02:01-restricted population. Industry-wide PRAME trial activity has slowed, with four trials started recently against ten older ones, a decline ratio of roughly 0.29. Because the trial's own primary measures are safety and tolerability rather than tumor response, the informative bar for this readout is a dose-limiting toxicity and serious-adverse-event rate that supports advancing the regimen past dose escalation, not a response rate.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.